BiotechTube
Nautilus Biotechnology

Nautilus Biotechnology

NAUT
United States· Est. 2016

Founded in 2016, Nautilus Biotechnology is on a mission to revolutionize biomedicine by making the full scale of the proteome accessible. The company's core technology, the Voyager Platform, employs Iterative Mapping to analyze billions of single protein molecules, offering comprehensive proteome coverage with single-molecule sensitivity and digital quantification. Nautilus is currently in an Early Access Program phase, collaborating with research institutions to validate its platform for applications in neurodegenerative disease and beyond, positioning itself as a potential disruptor in the multi-billion dollar proteomics market.

nautilus.bio

NAUT · Stock Price

USD 3.95+3.05 (+338.89%)
Market Cap: $517.6M

Historical price data

AI Company Overview

Founded in 2016, Nautilus Biotechnology is on a mission to revolutionize biomedicine by making the full scale of the proteome accessible. The company's core technology, the Voyager Platform, employs Iterative Mapping to analyze billions of single protein molecules, offering comprehensive proteome coverage with single-molecule sensitivity and digital quantification. Nautilus is currently in an Early Access Program phase, collaborating with research institutions to validate its platform for applications in neurodegenerative disease and beyond, positioning itself as a potential disruptor in the multi-billion dollar proteomics market.

Neurodegenerative DiseasesOncologyGeneral Biomarker Discovery

Technology Platform

The Voyager Platform uses Iterative Mapping, a single-molecule proteomics method that employs ultra-dense nano-arrays, multi-affinity probes, and machine learning to digitally quantify proteins and proteoforms with high sensitivity, dynamic range, and reproducibility.

Pipeline

1
1 drug in pipeline
DrugIndicationStageWatch
MDMAPost-Traumatic Stress DisorderPhase 2

Opportunities

The primary growth opportunity is the commercialization of the Voyager Platform into the multi-billion dollar proteomics research market.
Successfully demonstrating utility in high-value applications like neurodegenerative disease biomarker discovery and drug development partnerships with pharma could drive rapid adoption.
The platform's design for AI integration also positions it well for the growing field of multi-omic data analysis.

Risk Factors

Key risks include technical execution challenges in scaling a novel, complex platform, failure to achieve commercial adoption against entrenched mass spectrometry competitors, and the financial pressures of being a pre-revenue public company with a significant burn rate.
Intellectual property protection is also critical in a fast-moving field.

Competitive Landscape

Main competitors are established mass spectrometry companies (Thermo Fisher, Bruker) and affinity-based proteomics firms (Olink, SomaLogic). Nautilus differentiates through its single-molecule, digital counting approach, unique focus on proteoform analysis, and platform designed for comprehensive proteome coverage and simplified data output.